Financial health
- The company is unprofitable; at its current free-cash-flow burn it has roughly 1.4 years of cash runway.
ELVN Financials Enliven Therapeutics, Inc.
7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
Net income
ROEROA
Equity
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | — | -$104M | — | — | -22.6% | -21.8% | -$70M | — | $99M |
| 2024 | — | -$89M | — | — | -28.7% | -27.3% | -$73M | — | $124M |
| 2023 | — | -$72M | — | — | -29.1% | -26.3% | -$61M | — | $100M |
| 2022 | — | -$38M | — | — | 49.0% | -45.2% | -$33M | — | $76M |
| 2021 | — | -$25M | — | — | 57.7% | -21.8% | -$19M | — | $110M |
| 2020 | — | -$41M | — | — | 203.7% | -45.5% | -$37M | — | $48M |
| 2019 | — | -$23M | — | — | 48.0% | -70.5% | -$22M | — | $5M |
Net income
ROEROA
Equity
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$32M | — | — | -3.6% | -3.6% | -$19M | — | $136M |
| Mar '26 | — | -$24M | — | — | -5.2% | -5.1% | -$19M | — | $132M |
| Dec '25 | — | -$30M | — | — | -6.5% | -6.2% | -$16M | — | $99M |
| Sep '25 | — | -$20M | — | — | -4.2% | -4.1% | -$13M | — | $102M |
| Jun '25 | — | -$25M | — | — | -5.2% | -5.0% | -$17M | — | $119M |
| Mar '25 | — | -$29M | — | — | -9.9% | -9.4% | -$24M | — | $102M |
| Dec '24 | — | -$23M | — | — | -7.5% | -7.1% | -$17M | — | $124M |
| Sep '24 | — | -$23M | — | — | -8.0% | -7.6% | -$12M | — | $101M |
| Jun '24 | — | -$20M | — | — | -6.5% | -6.1% | -$20M | — | $97M |
| Mar '24 | — | -$23M | — | — | -7.2% | -6.6% | -$23M | — | $149M |
| Dec '23 | — | -$19M | — | — | -7.9% | -7.1% | -$12M | — | $100M |
| Sep '23 | — | -$21M | — | — | -7.9% | -7.6% | -$16M | — | $74M |
| Jun '23 | — | -$17M | — | — | -6.0% | -5.8% | -$12M | — | $126M |
| Mar '23 | — | -$15M | — | — | -5.1% | -4.9% | -$21M | — | $292M |
| Dec '22 | — | -$10M | — | — | 12.4% | -11.5% | -$8M | — | $76M |
| Sep '22 | — | -$11M | — | — | 15.5% | -17.9% | -$6M | — | $86M |
| Jun '22 | — | -$9M | — | — | 15.1% | -13.7% | -$7M | — | $92M |
| Mar '22 | — | -$9M | — | — | 17.1% | -10.6% | -$11M | — | $100M |
| Dec '21 | — | -$14M | — | — | 33.4% | -12.6% | -$12M | — | $110M |
| Sep '21 | — | -$14M | — | — | -13.7% | -12.8% | -$11M | — | $75M |
Frequently asked questions
Is ELVN growing its revenue and profit?
See the revenue and net-income charts above for Enliven Therapeutics, Inc.'s multi-year trend.
How much debt does ELVN have?
As of FY2025, Enliven Therapeutics, Inc. reported — of total debt against $99M of cash.
What is ELVN's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.